A Phase 2b Dose-Ranging Study to Evaluate the Efficacy and Safety of ENV-294 in Adults With Moderate-to-Severe Atopic Dermatitis
A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study to Evaluate the Efficacy and Safety of ENV-294 in Adult Participants With Moderate-to-Severe Atopic Dermatitis
Studieoversigt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
Undersøgelsestype
Undersøgelsestype
Tilmelding (Anslået)
Tilmelding
Fase
Fase
- Fase 2
Kontakter og lokationer
Studiekontakt
Studiekontakt
- Navn: Clinical Operations
- E-mail: env-294.clinicaltrials@enveda.com
Studiesteder
-
-
California
-
Encinitas, California, Forenede Stater, 92024
- Rekruttering
- Enveda Investigative Site
-
Los Angeles, California, Forenede Stater, 90045
- Rekruttering
- Enveda Investigative Site
-
Northridge, California, Forenede Stater, 91325
- Rekruttering
- Enveda Investigative Site
-
-
Florida
-
Boca Raton, Florida, Forenede Stater, 33486
- Rekruttering
- Enveda Investigative Site
-
-
Indiana
-
Indianapolis, Indiana, Forenede Stater, 46250
- Rekruttering
- Enveda Investigative Site
-
Plainfield, Indiana, Forenede Stater, 46168
- Rekruttering
- Enveda Investigative Site
-
-
Texas
-
Dallas, Texas, Forenede Stater, 75230
- Rekruttering
- Enveda Investigative Site
-
San Antonio, Texas, Forenede Stater, 78213
- Rekruttering
- Enveda Investigative Site
-
Sugar Land, Texas, Forenede Stater, 77479
- Rekruttering
- Enveda Investigative Site
-
-
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
- Voksen
- Ældre voksen
Tager imod sunde frivillige
Beskrivelse
Inclusion Criteria:
In order to participate in this study all participants must:
- Be at least 18 years of age at the time of signing the ICF.
- Have chronic AD (also known as atopic eczema) that was diagnosed at least 12 months prior to Screening.
- Have a history of inadequate response or intolerance to topical corticosteroids or other topical treatments for AD within 6 months before Screening and/or inadequate response to a systemic therapy within 12 months before Screening.
Have moderate-to-severe AD, at Screening and Baseline, as defined by the following criteria:
- A vIGA score of 3 (moderate) or 4 (severe)
- EASI score of ≥16
- Body surface area involvement of ≥10%
- Have PP-NRS score ≥4 Screening and Baseline - the baseline score refers to a weekly average.
- Use a bland emollient daily for at least 1 week prior to Day 1 and agree to continue using that same emollient daily at the same frequency (minimally, once daily) throughout the study.
- Participants of reproductive potential (male and female participants) must practice effective methods of contraception as per protocol.
Exclusion Criteria:
Participants are excluded if they:
- Have any clinically significant medical condition or physical/laboratory/ECG/vital signs abnormality that would, in the opinion of the investigator, put the participant at undue risk or interfere with interpretation of study results.
- Have clinically significant abnormalities in any of the clinical laboratory evaluations at Screening or Baseline as determined by the Investigator.
- Have the presence of any concomitant skin conditions (eg, psoriasis, seborrheic dermatitis) or have large tattoos that would interfere with clinical assessment, evaluation of AD, or treatment response as determined by the investigator.
- Have an ongoing clinically significant skin infection or is receiving treatment for infection that may interfere with assessment of AD as determined by the investigator.
- Are pregnant or breastfeeding or are planning to become pregnant during the duration of the study and for 90 days after the last administration of study drug.
- Are taking or have taken any prespecified prohibited therapies within a specific timeframe as determined by the Investigator.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Firedobbelt
Antal våben
Våben og indgreb
Deltagergruppe / ArmDeltagergruppe / Arm |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Placebo komparator: Placebo arm
|
Matching oral tablet that does not contain active drug.
Administered once daily by mouth for 12 weeks under the same conditions as the investigational product.
|
|
Eksperimentel: ENV-294 Treatment Arm (Dose 1)
|
ENV-294 er et forsøgslægemiddel til oral indtagelse, der leveres som tabletter.
Deltagerne modtager ENV-294 én gang dagligt gennem munden i 12 uger.
|
|
Eksperimentel: ENV-294 Treatment Arm (Dose 2)
|
ENV-294 er et forsøgslægemiddel til oral indtagelse, der leveres som tabletter.
Deltagerne modtager ENV-294 én gang dagligt gennem munden i 12 uger.
|
|
Eksperimentel: ENV-294 Treatment Arm (Dose 3)
|
ENV-294 er et forsøgslægemiddel til oral indtagelse, der leveres som tabletter.
Deltagerne modtager ENV-294 én gang dagligt gennem munden i 12 uger.
|
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Percent change in Eczema Area and Severity Index (EASI) score
Tidsramme: Baseline to Week 12
|
Baseline to Week 12
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
vIGA-respons
Tidsramme: Baseline til uge 12
|
Andel af deltagere der opnår en reduktion på ≥2 point fra baseline i valideret Global Investigator Assessment (vIGA) score og en score på 0 eller 1.
|
Baseline til uge 12
|
|
Incidence of Treatment Emergent Adverse Events
Tidsramme: Baseline to Week 12 and Week 16
|
Baseline to Week 12 and Week 16
|
|
|
EASI-75 Response
Tidsramme: Baseline to Week 12
|
Proportion of participants with at least 75% reduction from Baseline in EASI score
|
Baseline to Week 12
|
|
Percent change in Scoring Atopic Dermatitis (SCORAD)
Tidsramme: Baseline to Week 12
|
Baseline to Week 12
|
|
|
Patient-Reported Outcomes
Tidsramme: Baseline to Week 12
|
Change in Patient Oriented Eczema Measure (POEM)
|
Baseline to Week 12
|
|
Patient-Reported Outcomes
Tidsramme: Baseline to Week 12
|
Peak Pruritus Numerical Rating Scale (PP-NRS): proportion of participants who achieve weekly mean decrease from Baseline of ≥4 points
|
Baseline to Week 12
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Efterforskere
Efterforskere
- Studieleder: Gurpreet Ahluwalia, PhD, Enveda Therapeutics, Inc.
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Studiestart
Primær færdiggørelse (Anslået)
Primær færdiggørelse
Studieafslutning (Anslået)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- ENV-294-202
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .